GSK3B and breast carcinoma: Through in vivo and in vitro experiments, this study found that LOC610012 induces the downregulation of EP3 and GSK3β expression by inhibiting the expression of PTGS2, further leading to the excessive accumulation of intracellular ROS, ultimately inhibiting the activity of canine breast cancer cells.